Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856526 | 0.94 | LMNA (0.61) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL13176134 | 0.91 | LMNA (0.68) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL7904262 | 0.84 | ALDH1A1 (0.70) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL10726957 | 0.83 | SMN1; SMN2 (0.58) | LMNAALDH1A1POLBKDM4ESMN1; SMN2 | |
| SCHEMBL12626178 | 0.82 | KMT2A (0.56) | LMNASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL8723804 | 0.82 | LMNA (0.68) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL4384921 | 0.82 | LMNA (0.68) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL27728086 | 0.82 | LMNA (0.68) | LMNAGAAALDH1A1POLBKDM4E | |
| SCHEMBL8210784 | 0.81 | CD4 (0.58) | LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18506963 | 0.81 | POLB (0.68) | LMNAGAAALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | DRD4, DRD1, SLC10A6 | LMNA 2494/4885GAA 1776/4885ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.